Ocular Therapeutix (NASDAQ:OCUL) is scheduled to release its earnings data after the market closes on Wednesday, November 7th. Analysts expect Ocular Therapeutix to post earnings of ($0.36) per share for the quarter.
Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37). Ocular Therapeutix had a negative net margin of 2,814.72% and a negative return on equity of 143.32%. The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.35 million. On average, analysts expect Ocular Therapeutix to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ OCUL opened at $5.17 on Tuesday. The company has a current ratio of 4.92, a quick ratio of 4.91 and a debt-to-equity ratio of 0.21. Ocular Therapeutix has a 52 week low of $3.30 and a 52 week high of $8.28. The firm has a market capitalization of $202.22 million, a P/E ratio of -2.35 and a beta of 1.55.
Several brokerages recently commented on OCUL. ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. HC Wainwright set a $10.00 target price on shares of Ocular Therapeutix and gave the stock a “buy” rating in a research note on Friday, July 20th. Piper Jaffray Companies began coverage on shares of Ocular Therapeutix in a research note on Thursday, September 6th. They issued an “overweight” rating on the stock. Zacks Investment Research downgraded shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Finally, Cantor Fitzgerald set a $22.00 price target on shares of Ocular Therapeutix and gave the company a “buy” rating in a report on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $12.00.
In related news, CFO Donald Notman purchased 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were acquired at an average price of $6.29 per share, for a total transaction of $78,625.00. Following the completion of the acquisition, the chief financial officer now directly owns 17,300 shares in the company, valued at approximately $108,817. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Antony C. Mattessich purchased 20,000 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The stock was bought at an average price of $5.95 per share, for a total transaction of $119,000.00. Following the acquisition, the chief executive officer now owns 57,900 shares of the company’s stock, valued at $344,505. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 49,400 shares of company stock worth $302,912. 15.90% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in Ocular Therapeutix stock. Bank of New York Mellon Corp boosted its stake in Ocular Therapeutix Inc (NASDAQ:OCUL) by 13.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 94,294 shares of the biopharmaceutical company’s stock after acquiring an additional 11,276 shares during the period. Bank of New York Mellon Corp owned 0.24% of Ocular Therapeutix worth $636,000 at the end of the most recent reporting period. 56.96% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Ocular Therapeutix (OCUL) Scheduled to Post Earnings on Wednesday” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/11/06/ocular-therapeutix-ocul-scheduled-to-post-earnings-on-wednesday.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.
Recommended Story: How to Invest in an Index Fund
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.